The South Korean Fair Trade Commission (KFTC) has agreed to give up its exclusive rights to file complaints about antitrust cases, such as price collusion or supply restriction. Accordingly, such antitrust cases can also be directly investigated by the prosecution instead of the nation’s corporate overseer.
The agreement was made Tuesday, August 21, between KFTC Chairman Kim Sang-jo and Justice Minister Park Sang-ki. It is the first time for the KFTC to give up its rights since the introduction of the Fair Trade Act in 1980.
Currently, the prosecution can take an antitrust case to the court only when asked by the KFTC, which has exclusive rights over antitrust cases.
While it aims at protecting businesses from a flood of lawsuits by individuals and civic groups that may hinder their operation, there have been growing calls that the doors should be open wider since such restriction leads to poor protection of consumer rights.
The KFTC’s monopoly of such rights also prompted businesses to hire former officials, in a bid to avoid penalties using their connections with the KFTC.
The corrupt ties led to the worst job scandal in KFTC history, with a number of its former and current officials, including former KFTC Chairman Jeong Jae-chan and his deputy Kim Hack-hyun, being indicted for allegedly pressuring conglomerates to offer cushy jobs for its retirees between 2012 and last year.
The KFTC chairman said that its monopoly of such rights, coupled with unfair execution, was a fundamental cause of the job scandal.
Full Content: The Korea Herald
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Meta Begins Defense After FTC Concludes Case in Landmark Antitrust Trial
May 15, 2025 by
CPI
UK Data Bill Still No Closer to Passage As Parliamentary ‘Ping-Pong’ Drags On
May 15, 2025 by
CPI
Regeneron Pharmaceuticals Awarded $271.2M in Damages Against Amgen
May 15, 2025 by
CPI
FTC Chair Proposes 15% Staff Reduction Amid Budget Constraints
May 15, 2025 by
CPI
UK Urges Antitrust Watchdog to Prioritize Growth and Clarity in Business Regulation
May 15, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas